Significance of occult HBV infection in patients with chronic hepatitis C

Journal of the College of Physicians and Surgeons Pakistan

Volumn 16, Issue 3, 2006, Pages 192-195

  Anwar, Wasif ^a   Sarwar, Muhammad ^a   Hussain, Agha Babar ^a   Tariq, Waheed Uz Zaman ^b   Saif, Mohsin ^a  

^a AGA KHAN UNIVERSITY HOSPITAL   (Pakistan)

^b ARMED FORCES INSTITUTE OF PATHOLOGY   (Pakistan)

Author keywords

Chronic hepatitis C; Occult hepatitis B; Treatment response

Indexed keywords

ANTIVIRUS AGENT; INTERFERON; RIBAVIRIN; VIRUS DNA;

ADULT; ARTICLE; COMPARATIVE STUDY; DRUG COMBINATION; FOLLOW UP; GENETICS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HUMAN; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; TIME; TREATMENT OUTCOME;

ADULT; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; RIBAVIRIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 39049181319     PISSN: 1022386X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Sultana N, Qazllbash AA, Abdul Bari. Prevalence of anti-hepatitis C antibodies in patients with liver disease, Pak Armed Forces Med J 2000; 50: 9-13.
2. Ahmad S, Gull J, Bano KA, Aftab MA, Khokhar MS, Prevalence of anti-hepatitis C antibodies in healthy blood donors at Services Hospital. Lahore, Pak Postgrad Med J 2002; 13: 18-20.
3. Mumtaz S, Mehmood-ur-Rehman, Muzaffar M, Masood-ul- Hassan, Iqbal W, Frequency of seropositive blood donors for hepatitis B. C and HIV viruses in Railway Hospital, Rawalpind. Pak J Med Res 2002; 41: 51-53
4. Umar M, Bushra HT, Younis M, Bashir N. Clinical spectrum of chronic liver disease due to HBV, HCV and dual infection: a comparative study. Pak Gasimenterol 1999; 13(1-2): 47-50.
5. Khan M, Khalil-ur-Rehman, Haider Z, Shafqat F. Seromarkers of hepatitis B and C in patients with cirrhosis.J Coll Physicians Surg Pak 2002;12: 105-107
6. Zarski JP. Bonn B, Bastie A, Pawlotsky JM, Baud M, BostBezeaux F, et al. Characteristics of patients with dual infection by hepatitis B and C viruses. J Hepatol 1998; 28: 27-33. (Pubitemid 28122496)
7. Shlratori Y, Shiina S, Zhang PY, Ohno E, Okudaira T, Payawal DA, et al Does dual infection by hepatitis B and C viruses play an important role in the pathogenesis of hepatocellular carcinoma in Japan? Cancer 1997; 80: 2060-2067 (Pubitemid 27506018)
8. Cacciola I, Polliclno T, Squadrito G, Cerenzia G, Orlando ME, Raimondo G. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease, N Engl J Med 1999; 341: 22-26 (Pubitemid 29293716)
9. Raimondo G, Balsono C. Craxi A, Forinati F, Levrero M, Mondelli M, et al Occult hepatitis B virus infection, Dig Liver Dis 2000; 32:822-826
10. Conjeevaram HS, Lok AS. Occult: hepatitis B virus infection: a hidden menace. Hepatology 2001; 34: 204-206 (Pubitemid 32591501)
11. Besisik F, Karaca C, Akyüz F, Horosanli S, Onel D, Badur S, et al. Occult HBV infection and YMDD variants in hemodialysis patients with chronic HCV infection, J Hepatol 2003; 38: 506-510 (Pubitemid 36399255)
12. Hu K. Occult hepatitis B virus infection and its clinical implications. J Viral Hepat 2002; 9: 243-257 (Pubitemid 36002459)
13. Khattab E, Chemin I, Vuillermoz I, Vieus C, Mrani S, Guillaud O, et al. Analysis of HCV co-infection with occult hepatitis B virus in patients undergoing IFN therapy. J Clin Virol 2005; 33:150-157 (Pubitemid 40725310)
14. Kao JH, Chen PJ, Lai MY Chen DS. Occult hepatitis B virus infection and clinical outcomes of patients with chronic hepatitis C. J Clin Micrabiol 2002; 40: 4068-4071 (Pubitemid 35285791)
15. Fabris P, Brown D, Tositti G, Bozzola L, Giordani MT, Bevilacqua P. et al Occult hepatitis B virus infection does not affect liver histology or response to therapy with interferon alpha and ribavirin in intravenous drug users with chronic hepatitis C. J Clin Virol 2004; 29: 160-166 (Pubitemid 38201461)
16. Gianriini E, Ceppa P, Botta F, Fasoli A, Rornagnoll P, Ansaldl F, et al. Previous hepatitis B virus infection is associated with worse disease stage and occult hepatitis B virus infection has low prevalence and pathogenicity in hepatitis C virus-positive patients, Liver 2003; 23: 12-18 (Pubitemid 37265769)
17. Hasegawa I, Orito E, Tanaka Y, Hirashima. K, Sakakibara K, Sakuni M, et al impact of occult hepatitis B virus infection on efficacy and prognosis of interferon-alpha therapy for patients with chronic hepatitis C. Liver Int 2005; 25: 247-253 (Pubitemid 40500556)
18. Ferraro D, Bonura C. Giglio M, Di Stefano R, Almasio PL, Di Marco V, et al. Occult HBV infection and suppression of HCV replication in the early phase of combination therapy for chronic hepatitis C. J Biol Regul Homeost Agents 2003; 17; 172-175 (Pubitemid 37220850)
19. Georgiadou SP, Zachour K, Rigopoulou E, Liaskos C, Mina P, Gerovasilis F, et al. Occult hepatitis B virus infection in Greek patients with chronic hepatitis C and in patients with diverse nonviral hepatic diseases, J Viral Hepat 2004; 11; 358-365 (Pubitemid 38961881)
20. Hui CK, Lau E, Wu H, Monto A, Kim M, Luk JM, et al. Fibrosis progression in chronic hepatitis C patients with occult hepatitis B co-infection. J Clin Virol 2005; 35; 185-192